Phase I/II Open-Label Safety and Dose Finding Study of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B

Trial Profile

Phase I/II Open-Label Safety and Dose Finding Study of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs DTX 101 (Primary)
  • Indications Haemophilia B
  • Focus Adverse reactions; First in man
  • Sponsors Dimension Therapeutics
  • Most Recent Events

    • 10 May 2017 According to a Dimension Therapeutics media release, the company announced its decision to discontinue the development of DTX101 for the treatment of moderate/severe-to-severe hemophilia B based on the analysis of the data from this and other (CTP-260780) study which revealed it would not meet the company's minimum target product profile for continued development or future commercialization.
    • 10 May 2017 Status changed from active, no longer recruiting to discontinued, according to a Dimension Therapeutics media release.
    • 10 May 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top